The body endogenously produces all the cholesterol necessary for vital functions. Optimal LDL levels are around 40 mg/dL, similar to a newborn's. Higher levels, typically from diet, are not needed and function like a toxin, initiating atherosclerosis.
HDL cholesterol, typically seen as protective, can become dysfunctional in the presence of risk factors like smoking or obesity. This dysfunctional HDL then contributes to atherosclerosis instead of preventing it, challenging the simplistic 'good vs. bad' cholesterol narrative.
The silent nature of high cholesterol creates a psychological barrier. Patients who feel perfectly healthy are often unwilling to commit to lifelong treatment, even when their risk is high, leading to preventable cardiovascular events.
A critical gap exists in cancer care where cardiovascular risk factors are often ignored. As cancer treatments improve survival, patients are increasingly dying from preventable heart attacks and strokes, necessitating the specialized field of cardio-oncology.
Universal cholesterol screening in young children acts as a trigger for cascade screening, where parents (often in their 30s) and grandparents (50s) are also tested. This uncovers and allows for treatment of familial hypercholesterolemia across three generations from a single pediatric test.
Widespread adoption of preventive health measures faces a major political hurdle. Politicians on four-year election cycles are incentivized to fund programs with immediate effects, rather than long-term prevention initiatives that may take 20-30 years to show results.
The development of PCSK9 inhibitors, a powerful class of cholesterol-lowering drugs, originated not from studying disease but from studying healthy people with a genetic mutation causing exceptionally low LDL. This highlights the value of investigating positive outliers in human biology.
A major challenge in managing high cholesterol is patient adherence to daily medication for life. New therapies like Inclisiran use mRNA silencing and require only two injections per year, dramatically improving adherence for busy or non-compliant individuals.
Focusing solely on LDL is a mistake. Even individuals with a genetic mutation leading to lifelong low LDL levels can still have cardiovascular events if they have other unmanaged risk factors like metabolic syndrome, obesity, or diabetes, highlighting the need for a comprehensive approach.